[go: up one dir, main page]

PE20081371A1 - Derivados de acido 2-fenoxinicotinico como moduladores de ppar-alfa - Google Patents

Derivados de acido 2-fenoxinicotinico como moduladores de ppar-alfa

Info

Publication number
PE20081371A1
PE20081371A1 PE2007001214A PE2007001214A PE20081371A1 PE 20081371 A1 PE20081371 A1 PE 20081371A1 PE 2007001214 A PE2007001214 A PE 2007001214A PE 2007001214 A PE2007001214 A PE 2007001214A PE 20081371 A1 PE20081371 A1 PE 20081371A1
Authority
PE
Peru
Prior art keywords
halogen
ppar
derivatives
cyane
alkyl
Prior art date
Application number
PE2007001214A
Other languages
English (en)
Inventor
Heinrich Meier
Peter Kolkhof
Axel Kretschmer
Arounarith Tuch
Lars Barfacker
Grande Yolanda Cancho
Original Assignee
Bayer Healthcare Ag
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Bayer Healthcare Ag filed Critical Bayer Healthcare Ag
Publication of PE20081371A1 publication Critical patent/PE20081371A1/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D213/00—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members
    • C07D213/02—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members
    • C07D213/04—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D213/60—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D213/78—Carbon atoms having three bonds to hetero atoms, with at the most one bond to halogen, e.g. ester or nitrile radicals
    • C07D213/79—Acids; Esters
    • C07D213/80—Acids; Esters in position 3
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/06—Antihyperlipidemics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/04—Inotropic agents, i.e. stimulants of cardiac contraction; Drugs for heart failure
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Diabetes (AREA)
  • Hematology (AREA)
  • Obesity (AREA)
  • Hospice & Palliative Care (AREA)
  • Urology & Nephrology (AREA)
  • Vascular Medicine (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Pyridine Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)

Abstract

SE REFIERE A DERIVADOS DE ACIDO 2-FENOXI-6-FENIL-NICOTINICO Y 2-FENOXI-6-PIRIDILNICOTINICO DE FORMULA (I) EN DONDE R1 ES HALOGENO, CIANO, ALQUILO(C1-C4), ENTRE OTROS; R2 ES HALOGENO, CIANO, ALQUILO(C1-C6), ALCOXI(C1-C6) Y -NR9-C(=O)-R10 OPCIONALMENTE SUSTITUIDOS, n ES UN NUMERO DE 0 A 3; A ES N o C-R7; R3 ES H O FLUOR; R4 ES H, F, Cl, CN O ALQUILO(C1-C4); R5 ES H, HALOGENO, NITRO, CIANO, ENTRE OTROS; R6 Y R7 SON INDEPENDIENTEMENTE H, HALOGENO, NITRO, ENTRE OTROS; R8 ES H, METILO O TRIFLUOROMETILO; R12 ES H O FLUOR. SON SELECCIONADOS: ACIDO 2-(2-CLOROFENOXI)-6-[4-(TRIFLUROMETIL)FENIL]-NICOTINICO, ACIDO-2-(2-CLOROFENOXI)-6-(4-FLUORO-3-METILFENIL)-NICOTINICO, ENTRE OTROS. TAMBIEN SE REFIERE A COMPOSICIONES FARMACEUTICAS Y UN PROCEDIMIENTO DE PREPARACION. ESTOS COMPUESTOS SON MODULADORES DE PPAR-ALFA, SIENDO UTILES EN EL TRATAMIENTO DE ENFERMEDADES CARDIOVASCULARES, PARTICULARMENTE DISLIPIDEMIAS, ARTERIOSCLEROSIS E INSUFICIENCIA CARDIACA
PE2007001214A 2006-09-12 2007-09-11 Derivados de acido 2-fenoxinicotinico como moduladores de ppar-alfa PE20081371A1 (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
DE102006043520A DE102006043520A1 (de) 2006-09-12 2006-09-12 2-Phenoxynikotinsäure-Derivate und ihre Verwendung

Publications (1)

Publication Number Publication Date
PE20081371A1 true PE20081371A1 (es) 2008-10-16

Family

ID=38681456

Family Applications (1)

Application Number Title Priority Date Filing Date
PE2007001214A PE20081371A1 (es) 2006-09-12 2007-09-11 Derivados de acido 2-fenoxinicotinico como moduladores de ppar-alfa

Country Status (11)

Country Link
US (1) US20100298221A1 (es)
EP (1) EP2066635A2 (es)
JP (1) JP2010507569A (es)
AR (1) AR062586A1 (es)
CA (1) CA2662879A1 (es)
CL (1) CL2007002637A1 (es)
DE (1) DE102006043520A1 (es)
PE (1) PE20081371A1 (es)
TW (1) TW200829553A (es)
UY (1) UY30582A1 (es)
WO (1) WO2008031501A2 (es)

Families Citing this family (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE102007042754A1 (de) 2007-09-07 2009-03-12 Bayer Healthcare Ag Substituierte 6-Phenylnikotinsäuren und ihre Verwendung
EP2575821B1 (en) 2010-05-26 2015-08-12 Satiogen Pharmaceuticals, Inc. Bile acid recycling inhibitors and satiogens for treatment of diabetes, obesity, and inflammatory gastrointestinal conditions
JP6217938B2 (ja) 2011-10-28 2017-10-25 ルメナ ファーマシューティカルズ エルエルシー 小児の胆汁うっ滞性肝疾患の処置のための胆汁酸再循環阻害剤
CA2852957C (en) 2011-10-28 2020-08-04 Lumena Pharmaceuticals, Inc. Bile acid recycling inhibitors for treatment of hypercholemia and cholestatic liver disease
EP2968262A1 (en) 2013-03-15 2016-01-20 Lumena Pharmaceuticals, Inc. Bile acid recycling inhibitors for treatment of barrett's esophagus and gastroesophageal reflux disease
WO2014144650A2 (en) 2013-03-15 2014-09-18 Lumena Pharmaceuticals, Inc. Bile acid recycling inhibitors for treatment of primary sclerosing cholangitis and inflammatory bowel disease
BR112021015815A2 (pt) 2019-02-12 2022-01-18 Mirum Pharmaceuticals Inc Métodos para tratar colestase

Family Cites Families (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU2003225964B2 (en) * 2002-03-28 2008-11-20 Merck Sharp & Dohme Corp. Substituted 2,3-diphenyl pyridines
DE102005027150A1 (de) * 2005-03-12 2006-09-28 Bayer Healthcare Ag Pyrimidincarbonsäure-Derivate und ihre Verwendung

Also Published As

Publication number Publication date
CL2007002637A1 (es) 2008-03-14
DE102006043520A1 (de) 2008-03-27
EP2066635A2 (de) 2009-06-10
TW200829553A (en) 2008-07-16
WO2008031501A3 (de) 2011-04-14
JP2010507569A (ja) 2010-03-11
UY30582A1 (es) 2008-05-02
WO2008031501A2 (de) 2008-03-20
US20100298221A1 (en) 2010-11-25
AR062586A1 (es) 2008-11-19
CA2662879A1 (en) 2008-03-20

Similar Documents

Publication Publication Date Title
PE20081371A1 (es) Derivados de acido 2-fenoxinicotinico como moduladores de ppar-alfa
AR063211A1 (es) Derivados de 3-(piridin-3-il)acrilamida y 3-(piridin-3-il)propionamida, un metodo para su preparacion, una composicion farmaceutica que los comprende y su uso en la fabricacion de medicamentos para el tratamiento de enfermedades asociadas con el receptor vaniloide.
PE20060857A1 (es) Derivados de piridinilo y pirimidinilo sustituidos como moduladores del metabolismo y para tratar trastornos metabolicos
PE20080970A1 (es) Derivados de quinazolinona 5-sustituida y composiciones que los comprenden y metodos para utilizarlos
PE20091623A1 (es) DERIVADOS DE 1H-PIRAZOLO[3,4-b]PIRIDINA COMO INHIBIDORES DE RAF QUINASA
PE20110835A1 (es) Piridiloxi-indoles inhibidores del vegf-r2 y uso de los mismos para el tratamiento de enfermedades
PE20081393A1 (es) Derivados de quinolina como inhibidores de csf-1r
PE20081487A1 (es) DERIVADOS DE NICOTINAMIDA COMO INHIBIDORES DE 11ßHSD1
PE20120355A1 (es) DERIVADOS DE PIRAZOL COMO INHIBIDORES DE LA ENZIMA 11ßHSD1
PE20060525A1 (es) Compuestos heterociclicos como inhibidores de cetp
PE20061442A1 (es) Heterociclicos como agonistas del receptor de acido nicotinico para el tratamiento de dislipidemia
PE20060648A1 (es) Procesos para la preparacion de 2-(2,6-dioxopiperidin-3-il)-1-oxoisoindolinas sustituidas
PE20130402A1 (es) 5-fluoro-1h-pirazolopiridinas sustituidas y su uso
CY1108908T1 (el) Ενωσεις κινολινονης - καρβοξαμιδης ως αγωνιστες υποδοχεων 5-ητ4
PE20060150A1 (es) Antagonistas de cgrp seleccionados, composiciones farmaceuticas y procedimiento para su preparacion
PE20142019A1 (es) Nuevos derivados de acidos indaniloxidihidrobenzofuranilaceticos y sus usos como agonistas del receptor gpr40
NZ590784A (en) Pyrazolopyridine kinase inhibitors
EA200700099A1 (ru) Производные пиридина
PE20001483A1 (es) Acidos oxamicos y derivados como ligandos de receptores tiroideos
PE20091429A1 (es) 4-(4-ciano-2-tioaril)dihidropirimidinonas como inhibidores de la elastasa neutrofila humana (hne)
ES2564010T3 (es) Composición farmacéutica para tratar o prevenir el glaucoma
PE20140245A1 (es) Compuesto de furo[3,2-d]pirimidina
NO20063469L (no) Polyeheterosykliske forbindelser og deres anvendelse som metabotrofe glutamat reseptorantagonister
PE20060737A1 (es) 3-AMINO-PIRAZOL[3,4b] PIRIDINAS COMO INHIBIDORES DE PROTEINTIROSINQUINASAS Y SU PREPARACION
ATE277889T1 (de) Aminobenzophenone als inhibitoren von il-1beta und tnf-alpha

Legal Events

Date Code Title Description
FD Application declared void or lapsed